Tearsheet

IM Cannabis (IMCC)

Market Price (3/30/2026): $0.4867 | Market Cap: $1.6 Mil
Sector: Health Care | Industry: Pharmaceuticals

IM Cannabis (IMCC)

Market Price (3/30/2026): $0.4867
Market Cap: $1.6 Mil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -71%	Weak multi-year price returns 2Y Excs Rtn is -102%, 3Y Excs Rtn is -150%	Penny stock Mkt Price is 0.5
1	Attractive yield FCF Yield is 147%		Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -4.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -8.9%
2	Megatrend and thematic drivers Megatrends include Health & Wellness Trends. Themes include Cannabis-Based Wellness.		Debt is significant Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 893%
3			Weak revenue growth Rev Chg QQuarterly Revenue Change % is -14%
4			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -128%
5			High stock price volatility Vol 12M is 154%
6			Key risks IMCC key risks include [1] severe financial distress, Show more.

0	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -71%
1	Attractive yield FCF Yield is 147%
2	Megatrend and thematic drivers Megatrends include Health & Wellness Trends. Themes include Cannabis-Based Wellness.
3	Weak multi-year price returns 2Y Excs Rtn is -102%, 3Y Excs Rtn is -150%
4	Penny stock Mkt Price is 0.5
5	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -4.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -8.9%
6	Debt is significant Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 893%
7	Weak revenue growth Rev Chg QQuarterly Revenue Change % is -14%
8	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -128%
9	High stock price volatility Vol 12M is 154%
10	Key risks IMCC key risks include [1] severe financial distress, Show more.

Valuation, Metrics & Events

	3/30/26	2025	2024	2023	2022	2021
Share Price CYE	$0.49	$1.39	$2.33	$2.14	$5.85	$200.40
Market Cap CYE ($ Mil)	1.6	4.5	5.2	4.7	6.8	170.0
Total Debt ($ Mil)	15.7	15.7	15.7	13.3	36.0	14.9
Total Cash ($ Mil)	0.8	0.8	0.7	1.3	5.9	34.0
Enterprise Value ($ Mil)	16.4	20.2	20.9	18.0	42.8	184.9
Valuation Ratios
P/S TTM	0.0	0.1	0.1	0.1	0.2	5.5
P/EBIT TTM	-1.8	-5.2	-0.5	-0.3	-3.8	-34.0
P/E TTM	-0.8	-2.2	-0.4	-0.0	-0.1	-8.8
P/FCF TTM	0.6	1.9	1.0	-0.3	-0.3	-5.9
Sector Ratios
P/S TTM (Sector)	3.3	4.0	3.8	4.2	4.6	7.4
P/EBIT TTM (Sector)	-1.6	-1.8	-1.4	-1.4	-1.3	-3.0
P/E TTM (Sector)	-1.6	-1.9	-1.7	-1.6	-1.3	-3.4
P/FCF TTM (Sector)	-1.5	-1.7	-1.5	-1.5	-1.7	-3.6

	3/30/26	2025	2024
Share Price CYE	$0.49	$1.39	$2.33
Market Cap CYE ($ Mil)	1.6	4.5	5.2
Total Debt ($ Mil)	15.7	15.7	15.7
Total Cash ($ Mil)	0.8	0.8	0.7
Enterprise Value ($ Mil)	16.4	20.2	20.9
Valuation Ratios
P/S TTM	0.0	0.1	0.1
P/EBIT TTM	-1.8	-5.2	-0.5
P/E TTM	-0.8	-2.2	-0.4
P/FCF TTM	0.6	1.9	1.0
Sector Ratios
P/S TTM (Sector)	3.3	4.0	3.8
P/EBIT TTM (Sector)	-1.6	-1.8	-1.4
P/E TTM (Sector)	-1.6	-1.9	-1.7
P/FCF TTM (Sector)	-1.5	-1.7	-1.5

	IMCC	S&P 500
REVENUE GROWTH
Rev LTM ($ Bil)	0.1
Rev Chg Q	-13.9%	7.3%
Rev Chg LTM	5.1%	6.7%
Rev Chg 3Y Avg	7.1%	5.7%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.0
CFO LTM ($ Bil)	0.0
Net Inc LTM ($ Bil)	-0.0
Op Mgn LTM	-8.9%	18.6%
CFO/Rev LTM	4.9%	20.7%
Net Inc Mgn	-3.9%	12.8%
VALUATION	VERY LOW
P/S	0.0	3.1
P/CFO	0.6	14.8
P/FCF	0.6	19.4
P/E	-0.8	23.7
STABILITY	VERY POOR
Debt/Equity	9.91	0.22
Cash/Assets	0.02	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Licensed Medical Cannabis Patients in Israel	128320	7312024	Link
Average Selling Price per Gram of Dried Flower	6.09	6302024	Link

Upcoming
5/13/2026	Earnings Release	Rev: - EPS: -
5/18/2026	Earnings Release	Rev: $15 Mil (E) EPS: $0.09 (E)

Price Chart

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

IM Cannabis (IMCC) stock has lost about 70% since 11/30/2025 because of the following key factors:

1. Deteriorating Financial Performance and Liquidity Concerns. IM Cannabis reported challenging third-quarter 2025 financial results on November 13, 2025, just prior to the specified period. The company experienced a 13% decrease in gross profit to $2.7 million, a significant 68% increase in operating expenses to $6.9 million, and a net loss of $3.9 million. These figures, coupled with low cash and restricted cash totaling $2.3 million as of September 30, 2025, highlighted the company's financial strain. Further, in January 2026, IM Cannabis raised approximately US$2.17 million through note financings, with the first note having an 8% interest rate (rising to 14% on default) and conversion terms that could be dilutive at a floor of US$0.29, indicating ongoing capital needs and potential financial pressure.

2. Significant Strategic Pivot Away from Core Cannabis Business. On March 17, 2026, IM Cannabis announced a non-binding letter of intent to acquire a 51% stake in Blackaxe Technologies, a Polish defense-tech firm specializing in satellite intelligence and counter-UAS/cyber interception solutions. This proposed acquisition signals a drastic strategic shift away from the company's established medical cannabis operations in Israel and Germany. Such a substantial change in business focus to a completely different industry can create investor uncertainty and skepticism regarding the company's future direction and ability to execute on this new strategy, especially for a company already facing profitability challenges in its existing segment.

Show more

Stock Movement Drivers

Fundamental Drivers

The -71.8% change in IMCC stock from 11/30/2025 to 3/29/2026 was primarily driven by a -71.8% change in the company's P/S Multiple.

(LTM values as of)	11302025	3292026	Change
Stock Price ($)	1.82	0.51	-71.8%
Change Contribution By:
Total Revenues ($ Mil)	52	52	0.0%
P/S Multiple	0.1	0.0	-71.8%
Shares Outstanding (Mil)	3	3	0.0%
Cumulative Contribution			-71.8%

LTM = Last Twelve Months as of date shown

Market Drivers

11/30/2025 to 3/29/2026

	Return	Correlation
IMCC	-71.8%
Market (SPY)	-5.3%	4.5%
Sector (XLV)	-8.7%	-13.2%

Fundamental Drivers

The -77.9% change in IMCC stock from 8/31/2025 to 3/29/2026 was primarily driven by a -77.9% change in the company's P/S Multiple.

(LTM values as of)	8312025	3292026	Change
Stock Price ($)	2.32	0.51	-77.9%
Change Contribution By:
Total Revenues ($ Mil)	52	52	0.0%
P/S Multiple	0.1	0.0	-77.9%
Shares Outstanding (Mil)	3	3	0.0%
Cumulative Contribution			-77.9%

LTM = Last Twelve Months as of date shown

Market Drivers

8/31/2025 to 3/29/2026

	Return	Correlation
IMCC	-77.9%
Market (SPY)	0.6%	10.7%
Sector (XLV)	5.2%	-0.8%

Fundamental Drivers

The -75.2% change in IMCC stock from 2/28/2025 to 3/29/2026 was primarily driven by a -64.5% change in the company's P/S Multiple.

(LTM values as of)	2282025	3292026	Change
Stock Price ($)	2.07	0.51	-75.2%
Change Contribution By:
Total Revenues ($ Mil)	51	52	2.0%
P/S Multiple	0.1	0.0	-64.5%
Shares Outstanding (Mil)	2	3	-31.6%
Cumulative Contribution			-75.2%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2025 to 3/29/2026

	Return	Correlation
IMCC	-75.2%
Market (SPY)	9.8%	3.1%
Sector (XLV)	-2.1%	1.3%

Fundamental Drivers

The -91.7% change in IMCC stock from 2/28/2023 to 3/29/2026 was primarily driven by a -79.3% change in the company's P/S Multiple.

(LTM values as of)	2282023	3292026	Change
Stock Price ($)	6.17	0.51	-91.7%
Change Contribution By:
Total Revenues ($ Mil)	50	52	5.3%
P/S Multiple	0.2	0.0	-79.3%
Shares Outstanding (Mil)	1	3	-61.9%
Cumulative Contribution			-91.7%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2023 to 3/29/2026

	Return	Correlation
IMCC	-91.7%
Market (SPY)	69.4%	-0.0%
Sector (XLV)	18.4%	-0.2%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
IMCC Return	-64%	-97%	-63%	9%	-40%	-64%	-100%
Peers Return	-17%	-49%	-56%	-16%	-11%	-19%	-89%
S&P 500 Return	27%	-19%	24%	23%	16%	-5%	72%
Monthly Win Rates [3]
IMCC Win Rate	30%	17%	33%	42%	33%	0%
Peers Win Rate	25%	23%	38%	32%	42%	20%
S&P 500 Win Rate	75%	42%	67%	75%	67%	33%
Max Drawdowns [4]
IMCC Max Drawdown	-76%	-97%	-66%	-44%	-57%	-64%
Peers Max Drawdown	-29%	-51%	-65%	-29%	-50%	-21%
S&P 500 Max Drawdown	-1%	-25%	-1%	-2%	-15%	-5%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: TLRY, CRON, ACB, CGC, OGI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)

How Low Can It Go

Unique Key	Event	IMCC	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-99.7%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	30978.5%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days

Compare to TLRY, CRON, ACB, CGC, OGI

In The Past

IM Cannabis's stock fell -99.7% during the 2022 Inflation Shock from a high on 3/3/2021. A -99.7% loss requires a 30978.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About IM Cannabis (IMCC)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers cannabis flowers and strain specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, and pressed hash offerings under the WAGNERS and Highland Grow brands. The company serves medical patients and adult-use recreational consumers. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.

AI Analysis | Feedback

Here are 1-3 brief analogies for IM Cannabis (IMCC):

Like a Philip Morris or Altria, but for cannabis instead of tobacco.
Like an Anheuser-Busch InBev or Diageo, but specializing in cannabis products.

AI Analysis | Feedback

Cannabis Flowers: Medical cannabis products in flower form, offered under the IMC brand.
Strain-Specific Cannabis Extracts: Concentrated cannabis products tailored to specific strains, offered under the IMC brand.
Dried Flower: Cannabis in its dried form for medical or adult-use consumers, available under the WAGNERS and Highland Grow brands.
Pre-rolls: Convenient pre-rolled cannabis products, available under the WAGNERS and Highland Grow brands.
Pressed Hash Offerings: Concentrated cannabis resin in a pressed form, available under the WAGNERS and Highland Grow brands.

AI Analysis | Feedback

IM Cannabis Corp. (symbol: IMCC) is primarily engaged in the breeding, growing, and supply of medical and adult-use cannabis products in Israel, Germany, and Canada. While their products ultimately reach medical patients and adult-use recreational consumers, the company typically operates within regulated supply chains, meaning it sells its branded products (IMC, WAGNERS, Highland Grow) primarily to other businesses (B2B) rather than directly to individuals.

Due to competitive and commercial confidentiality reasons, IM Cannabis Corp. does not publicly disclose the specific names of its major customer companies. However, based on the standard operating models in the cannabis industry across its markets, its major customers fall into the following categories:

Licensed Cannabis Retailers and Provincial Distributors (Canada): In the Canadian adult-use market, IM Cannabis sells its recreational brands (WAGNERS, Highland Grow) to licensed provincial government distributors (e.g., Ontario Cannabis Store - OCS, BC Liquor Distribution Branch - BCLDB, Alberta Gaming, Liquor & Cannabis - AGLC) which then distribute to private licensed cannabis retailers. In some provinces, they may also sell directly to licensed private retailers.
Licensed Pharmacies and Pharmaceutical Wholesalers (Germany and Israel): For its medical cannabis products under the IMC brand, IM Cannabis supplies licensed pharmacies in both Germany and Israel. In Germany, this often involves sales through pharmaceutical wholesalers who then distribute to pharmacies. In Israel, the distribution model typically involves direct supply to licensed medical cannabis pharmacies.
Specialized Medical Cannabis Distributors (Germany and Israel): The company may also work with specialized distributors focused solely on medical cannabis products to reach pharmacies, clinics, and other licensed dispensing points in these regulated medical markets.

AI Analysis | Feedback

MediPharm Labs Corp. (TSX: LABS)

The Green Organic Dutchman Holdings Ltd. (CSE: TGOD)

AI Analysis | Feedback

Oren Shuster, Chief Executive Officer

Oren Shuster brings over two decades of entrepreneurial experience in founding and growing companies within the med-tech and technology/software industries. Prior to IM Cannabis, he co-founded E-wave, an international technology company providing software solutions, which today employs 1,000 professionals across several countries. Shuster has also held executive positions in the telecom and digital media sectors.

Asi Levi, Chief Financial Officer

Asi Levi was appointed Chief Financial Officer effective December 12, 2025, and brings over 15 years of experience in finance and controlling roles. His previous positions include serving as CFO at Water Ways Technologies Inc. and DekelOil CI, part of Dekel Agri-Vision Plc. He also held Controller roles at SciSparc Ltd. and A2Z Cust2Mate Solutions Corp. Levi has experience in overseeing fundraising efforts and managing financial planning, budgeting, and cash flow.

Richard Balla, CEO and Director, German Operations – Adjupharm GmbH

Richard Balla has nearly two decades of experience in senior roles within the German pharmaceutical industry, specializing in manufacturing, distribution, sales, and the parallel import of pharmaceuticals, medical devices, and cosmetics. Before leading Adjupharm, IM Cannabis' German subsidiary, Balla acted as a founder, early-stage shareholder, advisor, and director for multiple international companies in the pharmaceutical and medical cannabis sectors. He also served as Head of Market and Product Development at ACA Müller Pharma AG.

AI Analysis | Feedback

The key risks to IM Cannabis (IMCC) are: 1. Financial Vulnerability and Going Concern: IM Cannabis faces significant financial challenges, including persistent operating losses, negative cash flows, a high debt-to-equity ratio, and liquidity concerns as indicated by a low current ratio. The company's financial statements have included notes regarding its ability to continue as a going concern. It has also experienced issues with Nasdaq listing compliance due to not meeting minimum stockholders' equity requirements, though it has since regained compliance. This financial instability hampers its capacity for investment and sustainable growth. 2. Regulatory Changes and Market Fragmentation: The cannabis industry is subject to evolving and fragmented regulatory landscapes in the jurisdictions where IM Cannabis operates, specifically Israel and Germany. Changes in these regulations, such as expected shifts in the German market, could negatively impact the company's sales and overall market position. 3. Intense Competition and Lack of Scale: IM Cannabis operates within an intensely fragmented global cannabis market characterized by fierce price competition and high capital consumption. The company's relatively small market capitalization and its focus on the Israeli and German markets limit its scale, making it challenging to compete effectively with larger industry players and invest sufficiently in brand building and distribution.

AI Analysis | Feedback

The emergence and scaling of biosynthesis technologies (e.g., yeast or cellular fermentation) for producing cannabinoids, which could offer significantly lower costs, greater consistency, and scalability compared to traditional plant cultivation.

AI Analysis | Feedback

The addressable markets for IM Cannabis's main products and services vary by region, encompassing medical cannabis flowers and extracts, as well as dried flower, pre-rolls, and pressed hash for medical patients and adult-use recreational consumers in Israel, Germany, and Canada.

Canada

The total legal cannabis market in Canada was valued at approximately C$5.5 billion in the fiscal year ending March 31, 2025, which includes both adult-use recreational and medical sales.
Within this, dried cannabis flower (including pre-rolls) accounted for C$3.3 billion of total sales in the fiscal year ending March 31, 2025.
Inhaled cannabis extracts, a category that includes products like vape pens, hash, wax, and rosin, reached C$1.7 billion in sales, representing 31.1% of the total market in the fiscal year ending March 31, 2025.
The medical cannabis market in Canada generated revenue of USD 1,665.6 million in 2023 and is projected to reach USD 4,569.5 million by 2030. Domestic medical cannabis sales were approximately CA$355 million in the fiscal year 2023-24.

Germany

The estimated medical cannabis market in Germany is projected to exceed €670 million in 2025. Sales for medical cannabis are expected to reach €420 million in 2024 and are forecasted to grow to over €1 billion by 2028.
Another estimate for Germany's self-payer medical cannabis market suggests it could be worth as much as 2.9 billion euros annually.
The overall legal cannabis market in Germany was estimated at USD 2.04 billion in 2024 and is expected to reach USD 2.43 billion in 2025.
The cannabis extract market in Germany generated USD 15.0 million in revenue in 2023 and is anticipated to reach USD 77.9 million by 2030.

Israel

The medical cannabis market in Israel is projected to reach USD 1 billion by 2024.
Medical cannabis sales in Israel were estimated at approximately 1.1 billion NIS (about 240 million GBP) in 2023. These sales are forecasted to reach 2.1 billion NIS (about 456 million GBP) by the end of 2026 and approximately 2.4 billion NIS (about 520 million GBP) by 2028.
The cannabis extract market in Israel generated USD 7.7 million in revenue in 2023 and is expected to grow to USD 40.4 million by 2030.

AI Analysis | Feedback

IM Cannabis Corp. (NASDAQ: IMCC) is expected to drive future revenue growth over the next two to three years through a multi-faceted strategy focusing on key geographic markets, operational efficiencies, and potential new market expansion. These drivers include:

Expansion into the U.S. Market: IM Cannabis is actively exploring strategic opportunities to enter the United States cannabis market. This initiative is particularly driven by President Donald Trump's executive order signed on December 18, 2025, which aims to expedite the rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act, potentially unlocking significant new market opportunities for the company. The company has engaged financial advisors to guide its U.S. entry strategy.
Sustained Growth in the German Market: The company anticipates maintaining its growth trajectory in the German market throughout 2025. IM Cannabis expects to achieve its best sales quarter in Germany to date in the first quarter of 2025, building on a substantial 183% increase in German revenue in 2024 compared to 2023. The company's focus on this high-value market is a key part of its strategy for profitable growth.
Focus on High-Value Markets (Israel and Germany): IM Cannabis has strategically exited its Canadian operations to reallocate resources and concentrate on achieving sustainable and profitable growth in what it identifies as its highest-value markets: Israel and Germany. This focused approach aims to amplify the company's commercial and brand power in these established regions.
Enhanced Operational Efficiencies and Margin Improvement: The company is committed to active cost management and operational optimization to achieve sustainable profitability. Recent efforts have resulted in a significant decrease in operating expenses and an improvement in Adjusted EBITDA, indicating a more efficient operational structure that supports revenue generation and better margins.
Leveraging a Data-Driven Approach and Global Supply Chain: IM Cannabis utilizes a "transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain." This approach is expected to enable more effective product development, better alignment with market demands, and a consistent supply of premium medical cannabis products, contributing to sustained revenue growth across its operating markets.

AI Analysis | Feedback

Share Issuance

In January 2026, IM Cannabis raised US$2,171,660.40 through convertible notes and accompanying share purchase warrants, with the notes convertible into common shares and warrants exercisable at C$3.45 per share.
In May 2025, the company announced its intention to complete a non-brokered private placement of secured debentures for up to C$2,500,000, with the principal convertible into common shares.
Warrants from a 2024 private placement had their exercise price reduced from C$4.32 to C$3.43 and their expiration date extended to July 31, 2030, increasing the likelihood of future share issuance upon exercise.

Inbound Investments

In July 2025, IM Cannabis received a US$1 million tranche as part of a loan agreement for up to US$2 million with L.I.A. Pure Capital Ltd., which also granted the lender the right to recommend a director to the board.

Outbound Investments

In April 2025, IM Cannabis announced its intent to acquire the remaining 26% interest in Focus Medical Herbs Ltd. from Ewave Group Ltd., following a previous acquisition of a 74% interest through its subsidiary IMC Holdings.

Capital Expenditures

In the 12 months prior to June 2025, IM Cannabis reported capital expenditures of -$154,000.
Annual capital expenditures were -$0.79 million in 2024, -$5.98 million in 2023, -$9.72 million in 2022, and -$27.43 million in 2021.

Interactive Breakdown

null

null

Better Bets vs. IM Cannabis (IMCC)

Eli Lilly

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for IMCC: 7.1% | 0.0x)

AGL (39.7% | 0.0x)

Agilon Health

PIII (12.1% | 0.0x)

P3 Health Partners

Higher Rev Chg LTM (Value for IMCC: 5.1%)

LLY (44.7%)

Eli Lilly

UNH (11.8%)

UnitedHealth

AMGN (10.0%)

Amgen

ABBV (8.6%)

AbbVie

JNJ (6.0%)

Johnson & Johnson

Higher Rev Chg 3Y Avg (Value for IMCC: 7.1%)

LLY (32.1%)

Eli Lilly

ISRG (17.4%)

Intuitive Surgical

AMGN (11.9%)

Amgen

UNH (11.4%)

UnitedHealth

SYK (10.8%)

Stryker

Higher Op Mgn LTM (Value for IMCC: -8.9%)

LLY (45.6%)

Eli Lilly

MRK (34.0%)

Merck

ABBV (32.8%)

AbbVie

JNJ (27.2%)

Johnson & Johnson

UNH (4.2%)

UnitedHealth

Higher CFO/Rev LTM (Value for IMCC: 4.9%)

ABBV (31.1%)

AbbVie

AMGN (27.1%)

Amgen

JNJ (26.0%)

Johnson & Johnson

LLY (25.8%)

Eli Lilly

MRK (25.3%)

Merck

Higher FCF/Rev LTM (Value for IMCC: 4.7%)

ABBV (29.1%)

AbbVie

AMGN (22.0%)

Amgen

JNJ (20.5%)

Johnson & Johnson

MRK (19.0%)

Merck

LLY (9.2%)

Eli Lilly

Higher Total Yield (Value for IMCC: -124.3%)

MRK (8.9%)

Merck

UNH (8.5%)

UnitedHealth

JNJ (6.8%)

AMZN (3.6%)

Amazon.com

AAPL (3.6%)

Apple

NVDA (3.0%)

NVIDIA

Best Bets in Health Care

What You Pay

P/EBIT (Value for IMCC: -1.9x)

RPRX (12.2x)

Royalty Pharma

DOCS (18.6x)

Doximity

VEEV (30.8x)

Veeva Systems

HALO (15.0x)

Halozyme Therapeutics

UTHR (13.1x)

United Therapeutics

CPRX (11.2x)

Catalyst Pharmaceuticals

BMY (10.6x)

Bristol-Myers Squibb

RMD (17.4x)

ResMed

PBH (9.2x)

Prestige Consumer Healthcare

JNJ (17.3x)

Johnson & Johnson

P/E (Value for IMCC: -0.8x)

RPRX (25.8x)

Royalty Pharma

DOCS (18.6x)

Doximity

VEEV (31.1x)

Veeva Systems

HALO (22.9x)

Halozyme Therapeutics

UTHR (17.0x)

United Therapeutics

CPRX (13.4x)

Catalyst Pharmaceuticals

BMY (16.9x)

Bristol-Myers Squibb

RMD (21.6x)

ResMed

PBH (15.2x)

Prestige Consumer Healthcare

JNJ (21.6x)

Johnson & Johnson

What You Get

Rev Chg 3Y Avg (Value for IMCC: 7.1%)

RPRX (2.1%)

Royalty Pharma

DOCS (16.7%)

Doximity

VEEV (14.1%)

Veeva Systems

HALO (28.5%)

Halozyme Therapeutics

UTHR (18.1%)

United Therapeutics

CPRX (43.1%)

Catalyst Pharmaceuticals

BMY (1.5%)

Bristol-Myers Squibb

RMD (12.9%)

ResMed

PBH (-0.1%)

Prestige Consumer Healthcare

JNJ (2.6%)

Johnson & Johnson

Rev Chg LTM (Value for IMCC: 5.1%)

RPRX (5.1%)

Royalty Pharma

DOCS (15.9%)

Doximity

VEEV (16.3%)

Veeva Systems

HALO (37.6%)

Halozyme Therapeutics

UTHR (10.6%)

United Therapeutics

CPRX (19.8%)

Catalyst Pharmaceuticals

BMY (-0.2%)

Bristol-Myers Squibb

RMD (9.6%)

ResMed

PBH (-1.3%)

Prestige Consumer Healthcare

JNJ (6.0%)

Johnson & Johnson

Rev Chg Q (Value for IMCC: -13.9%)

RPRX (4.8%)

Royalty Pharma

DOCS (9.8%)

Doximity

VEEV (16.0%)

Veeva Systems

HALO (51.6%)

Halozyme Therapeutics

UTHR (7.4%)

United Therapeutics

CPRX (7.6%)

Catalyst Pharmaceuticals

BMY (1.3%)

Bristol-Myers Squibb

RMD (11.0%)

ResMed

PBH (-2.4%)

Prestige Consumer Healthcare

JNJ (9.1%)

Johnson & Johnson

FCF/Rev 3Y Avg (Value for IMCC: -4.6%)

RPRX (118.0%)

Royalty Pharma

DOCS (41.6%)

Doximity

VEEV (40.8%)

Veeva Systems

HALO (38.8%)

Halozyme Therapeutics

UTHR (34.1%)

United Therapeutics

CPRX (33.2%)

Catalyst Pharmaceuticals

BMY (27.9%)

Bristol-Myers Squibb

RMD (27.3%)

ResMed

PBH (22.3%)

Prestige Consumer Healthcare

JNJ (20.6%)

Johnson & Johnson

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	Day 7 of Loss Streak for IM Cannabis Stock with -30% Return (vs. -40% YTD) [10/28/2025]	10/29/2025
2	Day 6 of Loss Streak for IM Cannabis Stock with -29% Return (vs. -39% YTD) [10/27/2025]	10/28/2025
3	Can IM Cannabis Stock Recover If Markets Fall?	10/17/2025

	Title
0	ARTICLES

Trade Ideas

Select ideas related to IMCC.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
QDEL_2282026_Insider_Buying_45D_2Buy_200K	02282026	QDEL	QuidelOrtho	Insider	Insider Buys 45DStrong Insider Buying Companies with multiple insider buys in the last 45 days	0.0%	0.0%	0.0%
CHE_2272026_Dip_Buyer_FCFYield	02272026	CHE	Chemed	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	0.0%	0.0%	0.0%
LLY_2272026_Monopoly_xInd_xCD_Getting_Cheaper	02272026	LLY	Eli Lilly	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	0.0%	0.0%	0.0%
HAE_2202026_Dip_Buyer_FCFYield	02202026	HAE	Haemonetics	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	3.5%	3.5%	0.0%
IQV_2132026_Dip_Buyer_ValueBuy	02132026	IQV	IQVIA	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	7.1%	7.1%	-3.0%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
AGX	Argan	7.8	37.9%	81.1%
TBN	Tamboran Resources	0.9	25.6%	59.4%
U	Unity Software	8.3	13.5%	-56.0%
ADMA	ADMA Biologics	2.2	11.6%	-49.3%
METC	Ramaco Resources	1.0	11.4%	-13.6%
MEOH	Methanex	5.0	9.7%	64.8%
PTON	Peloton Interactive	1.9	8.8%	-28.1%
OXM	Oxford Industries	0.5	8.7%	3.0%
REX	REX American Resources	1.6	8.3%	47.7%
SGML	Sigma Lithium	1.2	7.8%	-20.7%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
BUR	Burford Capital	0.9	-47.1%	-53.6%
RCKT	Rocket Pharmaceuticals	0.4	-19.6%	7.4%
ZBIO	Zenas BioPharma	0.8	-17.8%	-49.8%
BKSY	BlackSky Technology	0.8	-17.2%	24.2%
PSNL	Personalis	0.6	-13.4%	-20.4%
SLS	SELLAS Life Sciences	0.5	-11.8%	15.8%
ANAB	AnaptysBio	1.6	-11.7%	18.4%
FLY	Firefly Aerospace	2.2	-11.6%	6.0%
INBX	Inhibrx Biosciences	0.9	-11.2%	-26.1%
YOU	Clear Secure	4.6	-11.2%	36.3%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
BCPC	Balchem	5.4	610.4%	8.9%
KOD	Kodiak Sciences	2.0	66.3%	32.3%
OLPX	Olaplex	1.3	51.9%	50.7%
CAR	Avis Budget	5.2	48.6%	15.7%
TBN	Tamboran Resources	0.9	36.0%	59.4%
ELVN	Enliven Therapeutics	2.4	33.8%	152.1%
TROX	Tronox	1.4	30.1%	120.3%
BORR	Borr Drilling	1.8	28.7%	50.1%
BRZE	Braze	2.5	25.5%	-32.9%
INDI	Indie Semiconductor	0.6	24.6%	-9.6%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
PIPR	Piper Sandler Cos	1.2	-75.2%	-12.4%
BUR	Burford Capital	0.9	-46.2%	-53.6%
WVE	WAVE Life Sciences	1.1	-45.9%	-62.6%
TASK	TaskUs	0.6	-37.8%	-15.9%
MAZE	Maze Therapeutics	1.4	-36.7%	-26.7%
ADMA	ADMA Biologics	2.2	-35.4%	-49.3%
CRCL	Circle Internet	21.5	-25.7%	18.1%
PLAY	Dave & Buster's Entertainment	0.3	-23.5%	-39.5%
EL	Estee Lauder Companies	24.3	-21.8%	-35.6%
NTSK	Netskope	1.9	-18.9%	-55.9%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
SOC	Sable Offshore	1.8	133.2%	104.5%
DAWN	Day One Biopharmaceuticals	2.2	101.0%	129.7%
VG	Venture Global	42.7	85.4%	157.4%
AAOI	Applied Optoelectronics	6.2	82.9%	181.7%
TNGX	Tango Therapeutics	2.1	68.9%	117.4%
AXTI	AXT	2.7	63.3%	270.8%
BW	Babcock & Wilcox Enterprises	1.5	61.7%	134.4%
PARR	Par Pacific	3.3	61.6%	86.9%
LWLG	Lightwave Logic	0.9	61.5%	123.3%
SM	SM Energy	3.8	56.2%	76.5%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
WVE	WAVE Life Sciences	1.1	-58.6%	-62.6%
BUR	Burford Capital	0.9	-51.4%	-53.6%
OLMA	Olema Pharmaceuticals	1.2	-44.0%	-45.3%
WING	Wingstop	4.3	-43.1%	-35.2%
FRMI	Fermi	3.7	-43.0%	-22.8%
PAR	PAR Technology	0.5	-43.0%	-64.7%
SES	SES AI	0.3	-42.6%	-45.1%
USAS	Americas Gold And Silver	1.5	-41.9%	7.6%
ITRG	Integra Resources	0.4	-41.0%	-36.2%
VITL	Vital Farms	0.6	-40.6%	-58.9%

Peer Comparisons

Peers to compare with:

Financials

	IMCC	TLRY	CRON	ACB	CGC	OGI	Median
Name	IM Canna.	Tilray B.	Cronos	Aurora C.	Canopy G.	Organigr.
Mkt Price	0.51	6.32	2.50	3.20	0.89	1.31	1.91
Mkt Cap	0.0	0.7	1.0	0.2	0.3	0.2	0.2
Rev LTM	52	837	147	373	278	280	279
Op Inc LTM	-5	-75	-19	-55	-50	-12	-35
FCF LTM	2	-68	-0	-31	-87	-38	-34
FCF 3Y Avg	-3	-68	-14	-61	-219	-30	-45
CFO LTM	3	-28	26	-10	-79	-19	-15
CFO 3Y Avg	-2	-37	1	-42	-211	-14	-25

Growth & Margins

	IMCC	TLRY	CRON	ACB	CGC	OGI	Median
Name	IM Canna.	Tilray B.	Cronos	Aurora C.	Canopy G.	Organigr.
Rev Chg LTM	5.1%	1.0%	24.6%	16.5%	0.6%	68.6%	10.8%
Rev Chg 3Y Avg	7.1%	11.9%	19.1%	21.1%	-6.7%	27.4%	15.5%
Rev Chg Q	-13.9%	3.1%	47.0%	6.8%	-0.3%	48.7%	5.0%
QoQ Delta Rev Chg LTM	-3.8%	0.8%	10.8%	1.6%	-0.1%	8.0%	1.2%
Op Mgn LTM	-8.9%	-9.0%	-13.3%	-14.8%	-18.0%	-4.3%	-11.1%
Op Mgn 3Y Avg	-24.1%	-15.7%	-51.8%	-15.9%	-43.7%	-17.9%	-21.0%
QoQ Delta Op Mgn LTM	4.3%	1.8%	5.2%	-8.0%	2.3%	1.6%	2.0%
CFO/Rev LTM	4.9%	-3.4%	17.6%	-2.6%	-28.3%	-6.9%	-3.0%
CFO/Rev 3Y Avg	-3.9%	-4.6%	-5.1%	-15.4%	-73.6%	-7.0%	-6.1%
FCF/Rev LTM	4.7%	-8.2%	-0.1%	-8.4%	-31.1%	-13.5%	-8.3%
FCF/Rev 3Y Avg	-4.6%	-8.5%	-16.1%	-21.3%	-76.3%	-15.7%	-15.9%

Valuation

	IMCC	TLRY	CRON	ACB	CGC	OGI	Median
Name	IM Canna.	Tilray B.	Cronos	Aurora C.	Canopy G.	Organigr.
Mkt Cap	0.0	0.7	1.0	0.2	0.3	0.2	0.2
P/S	0.0	0.8	6.5	0.5	1.1	0.6	0.7
P/EBIT	-1.9	-0.3	-49.0	-2.5	-1.1	-14.8	-2.2
P/E	-0.8	-0.3	-101.2	-2.1	-0.9	9.7	-0.9
P/CFO	0.7	-24.5	37.0	-18.9	-3.9	-9.1	-6.5
Total Yield	-124.3%	-302.2%	-1.0%	-46.7%	-106.2%	10.3%	-76.4%
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FCF Yield 3Y Avg	-59.3%	-37.8%	-1.7%	-26.5%	-57.3%	-20.1%	-32.2%
D/E	9.4	0.5	0.0	0.6	0.8	0.0	0.5
Net D/E	8.9	0.0	-0.9	-0.0	-0.4	0.0	-0.0

Returns

	IMCC	TLRY	CRON	ACB	CGC	OGI	Median
Name	IM Canna.	Tilray B.	Cronos	Aurora C.	Canopy G.	Organigr.
1M Rtn	-24.7%	-19.7%	-6.4%	-16.7%	-20.2%	-8.4%	-18.2%
3M Rtn	-64.2%	-34.2%	-6.0%	-28.7%	-24.9%	-26.8%	-27.8%
6M Rtn	-71.1%	-45.0%	-4.9%	-34.2%	-33.3%	-22.5%	-33.7%
12M Rtn	-72.1%	-4.6%	39.7%	-27.8%	-9.4%	27.2%	-7.0%
3Y Rtn	-88.5%	-74.9%	32.3%	-51.9%	-94.9%	-48.6%	-63.4%
1M Excs Rtn	-21.2%	-13.1%	1.4%	-9.9%	-13.8%	-2.5%	-11.5%
3M Excs Rtn	-57.3%	-29.6%	-0.6%	-21.9%	-23.7%	-17.4%	-22.8%
6M Excs Rtn	-67.6%	-43.3%	-1.7%	-31.8%	-31.2%	-21.6%	-31.5%
12M Excs Rtn	-82.4%	-15.0%	27.4%	-38.9%	-26.4%	13.3%	-20.7%
3Y Excs Rtn	-149.7%	-155.6%	-29.5%	-116.5%	-157.0%	-110.6%	-133.1%

FDIC Bank Data

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	6/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	8/12/2025	3/31/2025	3/28/2024	3/29/2023	4/4/2022	4/23/2021	4/21/2020
Key Financials
Total Revenue	52	54	49	54	34	16	9
EBITDA	1	-6	-3	-17	6	-7	-6
Operating Income	-5	-10	-12	-23	-23	-8	-7
Net Income	-2	-11	-9	-189	-18	-29	-7
EPS	-0.63	-4.51	-4.45	-157.83	-18.36	-11.40	-13.80
Growth Rates
Total Revenue Growth	5.1%	10.7%	-10.2%	59.6%	114.3%	75.1%	∞%
EBITDA Growth	115.3%	-120.2%	83.4%	-368.6%	188.6%	-16.9%	-5027.5%
Operating Income Growth	70.7%	15.9%	45.9%	2.3%	-179.4%	-24.1%	-5557.2%
Net Income Growth	85.7%	-11.4%	95.0%	-963.4%	38.1%	-293.6%	-5844.5%
Margins
EBITDA Margin	2.0%	-11.4%	-5.7%	-30.8%	18.3%	-44.3%	-66.4%
Operating Income Margin	-8.9%	-18.9%	-24.9%	-41.4%	-67.6%	-51.9%	-73.2%
Net Income Margin	-3.9%	-19.6%	-19.5%	-347.6%	-52.2%	-180.6%	-80.4%
Cash & Debt
Total Cash	1	1	2	2	17	9	14
Total Debt	16	18	14	12	29	1	1
Net Debt / (Cash)	15	17	12	9	12	-8	-13
Cash Flows
Net Cash from Operations	3	-1	-8	-13	-34	-8	-6
Free Cash from Operations	2	-1	-9	-14	-39	-11	-8
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	8/12/2025	5/15/2025	3/31/2025	11/14/2024	8/14/2024	5/8/2024	3/28/2024	11/13/2023	8/14/2023	5/15/2023	3/29/2023	11/14/2022
Key Financials Quarterly
Total Revenue	13	12	13	14	15	12	11	12	13	13	14	14
Ebitda	2	1	-1	-1	-2	-5	2	-2	-1	1	-7	-4
Operating Income	-0	0	-4	-1	-3	-6	-5	-2	-1	-3	-7	-6
Net Income	-0	0	-1	-1	-3	-6	-3	-2	-3	-1	-33	-128
EPS	-0.09	0.09	-0.22	-0.41	-1.36	-2.52	-1.50	-0.96	-1.56	-0.30	-26.18	-10.86
Key Financials TTM
Total Revenue TTM	52	54	54	51	50	48	49	53	54	54	54	50
Ebitda TTM	1	-3	-9	-6	-7	-5	0	-8	-11	-10	-15	9
Operating Income TTM	-5	-7	-13	-15	-16	-14	-12	-14	-17	-21	-22	-24
Net Income TTM	-2	-5	-11	-13	-14	-15	-10	-40	-165	-181	-189	-169
Growth Rates Quarterly
Total Revenue Growth	-13.9%	3.6%	24.6%	12.2%	11.7%	-3.7%	-26.0%	-12.7%	4.0%	-3.6%	45.9%	76.2%
EBITDA Growth	185.0%	112.6%	-154.6%	68.2%	-268.8%	-780.5%	128.2%	57.5%	-122.2%	117.5%	-140.9%	39.7%
Operating Income Growth	87.8%	102.8%	31.9%	57.8%	-102.3%	-68.9%	24.1%	59.1%	71.6%	34.8%	22.2%	32.0%
Net Income Growth	89.8%	102.9%	69.3%	57.1%	12.4%	-595.2%	90.0%	98.3%	81.8%	90.8%	-156.1%	-2882.2%
Margins Quarterly
EBITDA Margin	15.8%	5.0%	-8.0%	-3.6%	-16.0%	-40.7%	18.3%	-12.8%	-4.8%	5.8%	-47.9%	-26.2%
Operating Income Margin	-2.8%	1.3%	-26.4%	-6.9%	-19.5%	-46.7%	-48.3%	-18.3%	-10.7%	-26.6%	-47.1%	-39.0%
Net Income Margin	-2.4%	1.4%	-7.6%	-6.6%	-20.5%	-49.9%	-30.7%	-17.4%	-26.2%	-6.9%	-228.4%	-901.8%
Cash & Debt
Total Cash	1	1	1	2	1	1	2	1	1	1	2	3
Total Debt	16	16	18	16	16	14	14	12	13	10	12	8
Net Debt / (Cash)	15	14	17	14	15	12	12	10	12	9	9	5
Cash Flows Quarterly
FCF from Operations	-0	4	-4	3	1	-1	-0	5	-7	-6	-3	1
Cash Flows TTM
FCF from Operations TTM	3	4	-1	3	6	-3	-8	-10	-15	-9	-13	-5
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-0.4%	0.2%	-4.8%	-1.3%	-3.3%	-8.0%	-7.5%	-3.3%	-2.0%	-4.8%	-9.9%	-8.3%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-1.6%	-2.2%	-4.2%	-5.2%	-5.7%	-5.2%	-4.4%	-5.0%	-6.2%	-7.2%	-7.9%	-8.9%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021
Cannabis products	44	48	26
Other products	5	6	8
Adult-use recreational cannabis product			0
Single Segment				16
Total	49	54	34	16

Price Behavior

Price Behavior

Market Price	$0.51
Market Cap ($ Bil)	0.0
First Trading Date	03/01/2021
Distance from 52W High	-91.7%
	50 Days	200 Days
DMA Price	$0.97	$1.80
DMA Trend	down	down
Distance from DMA	-47.1%	-71.5%
	3M	1YR
Volatility	96.8%	153.9%
Downside Capture	1.63	0.65
Upside Capture	-286.88	-58.93
Correlation (SPY)	14.3%	3.0%

IMCC Betas & Captures as of 2/28/2026

	1M	2M	3M	6M	1Y	3Y
Beta	2.31	2.33	1.02	1.35	0.26	-0.00
Up Beta	2.35	1.85	0.43	2.27	-0.03	0.04
Down Beta	3.12	4.50	2.03	0.89	0.99	1.86
Up Capture	-277%	-139%	-183%	-39%	-27%	-7%
Bmk +ve Days	9	20	31	70	142	431
Stock +ve Days	4	14	22	44	101	313
Down Capture	622%	385%	328%	242%	69%	-272%
Bmk -ve Days	12	21	30	54	109	320
Stock -ve Days	16	26	38	76	141	422

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with IMCC
IMCC	-76.9%	152.3%	-0.31	-
Sector ETF (XLV)	0.3%	17.6%	-0.13	1.5%
Equity (SPY)	14.5%	18.9%	0.59	3.8%
Gold (GLD)	50.2%	27.7%	1.46	3.9%
Commodities (DBC)	17.8%	17.6%	0.85	-1.4%
Real Estate (VNQ)	0.4%	16.4%	-0.15	6.3%
Bitcoin (BTCUSD)	-23.7%	44.2%	-0.49	6.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with IMCC
IMCC	-75.7%	122.9%	-0.61	-
Sector ETF (XLV)	6.0%	14.5%	0.23	4.5%
Equity (SPY)	11.8%	17.0%	0.54	8.0%
Gold (GLD)	20.7%	17.7%	0.96	2.1%
Commodities (DBC)	11.6%	18.9%	0.50	4.1%
Real Estate (VNQ)	3.0%	18.8%	0.07	7.7%
Bitcoin (BTCUSD)	4.0%	56.6%	0.29	6.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with IMCC
IMCC	-51.5%	122.4%	-0.63	-
Sector ETF (XLV)	9.7%	16.5%	0.48	4.3%
Equity (SPY)	14.0%	17.9%	0.67	7.9%
Gold (GLD)	13.3%	15.8%	0.70	2.2%
Commodities (DBC)	8.2%	17.6%	0.39	4.0%
Real Estate (VNQ)	4.7%	20.7%	0.19	7.6%
Bitcoin (BTCUSD)	66.4%	66.8%	1.06	6.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	3132026
Short Interest: Shares Quantity	0.0 Mil
Short Interest: % Change Since 2282026	-12.6%
Average Daily Volume	0.0 Mil
Days-to-Cover Short Interest	1
Basic Shares Quantity	3.3 Mil
Short % of Basic Shares	0.2%

Returns Analyses

	Title
0	Can IM Cannabis Stock Recover If Markets Fall?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
SUMMARY STATS
# Positive	0	0	0
# Negative	0	0	0
Median Positive
Median Negative
Max Positive
Max Negative

SEC Filings

Expand for More

Report Date	Filing Date	Filing
06/30/2025	08/12/2025	6-K
03/31/2025	05/15/2025	6-K
12/31/2024	03/31/2025	20-F
09/30/2024	11/14/2024	6-K
06/30/2024	08/14/2024	6-K
03/31/2024	05/08/2024	6-K
12/31/2023	03/28/2024	20-F
09/30/2023	11/13/2023	6-K
06/30/2023	08/14/2023	6-K
03/31/2023	05/15/2023	6-K
12/31/2022	03/29/2023	20-F
09/30/2022	11/14/2022	6-K
06/30/2022	08/15/2022	6-K
03/31/2022	05/12/2022	6-K
12/31/2021	04/04/2022	40-F
09/30/2021	11/24/2021	6-K

Recent Forward Guidance [BETA]

Latest: null Earnings Reported N/A/N/A/N/A | Prior: null Earnings Reported N/A/N/A/N/A

null

Insider Activity

Expand for Morenull

IMCC Trade Sentinel

Stock Conviction

null

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

null

Diversification Alternatives

How Is The Market Pricing IMCC?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What IMCC Makes & Who Pays

TTM figures based on

IMCC Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

IM Cannabis (IMCC)

Market Price (3/30/2026): $0.4867 | Market Cap: $1.6 MilSector: Health Care | Industry: Pharmaceuticals

IM Cannabis (IMCC)

Market Price (3/30/2026): $0.4867Market Cap: $1.6 MilSector: Health CareIndustry: Pharmaceuticals

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About IM Cannabis (IMCC)

Canada

Germany

Israel

Interactive Breakdown

Better Bets vs. IM Cannabis (IMCC)

INDUSTRY: Pharmaceuticals

Higher Rev Chg LTM (Value for IMCC: 5.1%)

Higher Rev Chg 3Y Avg (Value for IMCC: 7.1%)

Higher Op Mgn LTM (Value for IMCC: -8.9%)

Higher CFO/Rev LTM (Value for IMCC: 4.9%)

Higher FCF/Rev LTM (Value for IMCC: 4.7%)

Higher Total Yield (Value for IMCC: -124.3%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for IMCC: 7.1% | 0.0x)

Higher Rev Chg LTM (Value for IMCC: 5.1%)

Higher Rev Chg 3Y Avg (Value for IMCC: 7.1%)

Higher Op Mgn LTM (Value for IMCC: -8.9%)

Higher CFO/Rev LTM (Value for IMCC: 4.9%)

Higher FCF/Rev LTM (Value for IMCC: 4.7%)

Higher Total Yield (Value for IMCC: -124.3%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for IMCC: 7.1% | 0.0x)

Higher Rev Chg LTM (Value for IMCC: 5.1%)

Higher Rev Chg 3Y Avg (Value for IMCC: 7.1%)

Higher Op Mgn LTM (Value for IMCC: -8.9%)

Higher CFO/Rev LTM (Value for IMCC: 4.9%)

Higher FCF/Rev LTM (Value for IMCC: 4.7%)

Higher Total Yield (Value for IMCC: -124.3%)

Best Bets in Health Care

P/EBIT (Value for IMCC: -1.9x)

P/E (Value for IMCC: -0.8x)

Rev Chg 3Y Avg (Value for IMCC: 7.1%)

Rev Chg LTM (Value for IMCC: 5.1%)

Rev Chg Q (Value for IMCC: -13.9%)

FCF/Rev 3Y Avg (Value for IMCC: -4.6%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Market Price (3/30/2026): $0.4867 | Market Cap: $1.6 Mil
Sector: Health Care | Industry: Pharmaceuticals

Market Price (3/30/2026): $0.4867
Market Cap: $1.6 Mil
Sector: Health Care
Industry: Pharmaceuticals